Abbott experienced strong growth in several segments, particularly in Medical Devices and EPD, and achieved significant EPS growth. However, challenges persist in the Diagnostics segment due to declining COVID testing sales and issues in the China market. The impact of tariffs also presents a headwind, but overall performance remains resilient.

Company Guidance -

Q3 2025

During the second quarter of 2025, Abbott demonstrated robust financial performance with high single-digit organic sales growth, excluding COVID testing sales, amounting to 7.5% for the quarter and 8% for the first half of the year. The company also achieved over 100 basis points of margin expansion in both gross and operating margins, alongside a 16% sequential growth in adjusted earnings per share, reaching $1.26, which exceeded consensus estimates. Despite a 1.5% decline in diagnostics sales due to reduced COVID testing and challenges in China, Abbott's core lab diagnostics grew by 8% outside China. Nutrition sales rose by 3.5% driven by a 6.5% increase in adult nutrition, while Medical Devices saw a 12% growth, propelled by double-digit growth in diabetes care, heart failure, and electrophysiology. The company's strategic initiatives, including biosimilar regulatory submissions in emerging markets and advancements in mitral valve replacement technologies, underscore its commitment to sustainable growth and innovation. Abbott forecasts continued high single-digit growth with expectations for favorable foreign exchange impacts and resilience against headwinds in diagnostics.

Strong Sales Growth

Abbott delivered high single-digit sales growth excluding COVID testing, with a 7.5% increase in the second quarter and an 8% increase in the first half of 2025.

Record Performance in EPD

Sales in EPD grew nearly 8% in the quarter, surpassing $1 billion in quarterly sales for the first time, driven by strong performance in key markets including India, China, and other regions.

Medical Devices Success

Medical Devices sales grew 12% driven by double-digit growth in diabetes care, heart failure, structural heart, electrophysiology, and cardiac rhythm management.

Diabetes Care Growth

Sales of continuous glucose monitors reached $1.9 billion in the quarter, growing 19.5%.

EPS Growth

Second quarter adjusted earnings per share were $1.26, reflecting 11% growth versus the prior year and 16% growth on a sequential basis.

Abbott Laboratories (ABT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ABT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 15, 2025	2025 (Q3)	1.30 / -	1.21	―	―	―
Jul 17, 2025	2025 (Q2)	1.26 / 1.26	1.14	10.53% (+0.12)
Apr 16, 2025	2025 (Q1)	1.07 / 1.09	0.98	11.22% (+0.11)
Jan 22, 2025	2024 (Q4)	1.34 / 1.34	1.19	12.61% (+0.15)
Oct 16, 2024	2024 (Q3)	1.20 / 1.21	1.14	6.14% (+0.07)
Jul 18, 2024	2024 (Q2)	1.10 / 1.14	1.08	5.56% (+0.06)
Apr 17, 2024	2024 (Q1)	0.95 / 0.98	1.03	-4.85% (-0.05)
Jan 24, 2024	2023 (Q4)	1.19 / 1.19	1.03	15.53% (+0.16)
Oct 18, 2023	2023 (Q3)	1.10 / 1.14	1.15	-0.87% (-0.01)
Jul 20, 2023	2023 (Q2)	1.05 / 1.08	1.43	-24.48% (-0.35)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ABT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 17, 2025	$131.74	$120.51	-8.52%
Apr 16, 2025	$125.66	$129.12	+2.75%
Jan 22, 2025	$115.73	$116.71	+0.85%
Oct 16, 2024	$114.40	$116.14	+1.52%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.